Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04596657
Other study ID # 20-455
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 27, 2020
Est. completion date October 19, 2023

Study information

Verified date December 2023
Source The Cooper Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Cooper vitamin D3 study is a randomized study investigating whether daily vitamin D3 supplementation can prevent respiratory tract infections, influenza-like illness and covid-19 in hospital workers.


Description:

Influenza-like illness and covid-19 were added to this summary because the protocol uses respiratory tract infections and influenza-like illness interchangeably. Influenza-like illness is more accurate. Protocol amendments: Protocol title was amended to include covid-19. Minimum age was changed from 52 to 18, expanding the sample size. Exclusion criteria re vitamin D intake was changed from >5000 to >=5000 IU.


Recruitment information / eligibility

Status Completed
Enrollment 877
Est. completion date October 19, 2023
Est. primary completion date November 23, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hospital worker - Age 18 years or older Exclusion Criteria: - History of hypercalcemia - History of nephrolithiasis - History of intolerance to vitamin D3 supplements - Use of calcium at a dose > 600 mg/day (individuals using a dose greater than 600 mg of calcium per day will be asked to limit the amount to 600 mg unless they have been directed by their physician to be taking more than 600 mg/day of calcium. If the latter is true the potential subject will be excluded from the study.) - Use of vitamin D at a daily dose > 5000 IU* - Use of aluminum-containing phosphate binders in patients with renal failure - Use of calcipotriene - Use of digoxin - Use of thiazide diuretics if using: - hydrochlorothiazide at a daily dose > 37.5 mg - indapamide at a daily dose > 1.25 mg - chlorthalidone at a daily dose > 12.5 mg - metolazone at a daily dose > 2.5 mg - methyclothiazide at a daily dose > 2.5 mg - chlorothiazide at a daily dose > 250 mg - metolazone at a daily dose > 0.5 mg - bendroflumethiazide at a daily dose > 2.5 mg - polythiazide at a daily dose > 1 mg - hydroflumethiazide at a daily dose > 25 mg - Conditions that are associated with a risk of modified vitamin D metabolism - Known allergy to wool - Current enrollment in another study - Life expectancy <1 month at time of screening - Cognitive impairment precluding the ability to provide informed consent - Pregnant or trying to become pregnant - Employee is team member on the present study - If potential participants are found to be using vitamin D supplementation upon screening at a daily dose =5000 IU/day, they will be eligible for participation by switching to the study dose. If potential participants are taking a multiple vitamin or calcium supplement and there is less than or equal to 800 IU vitamin D in it, they can continue the multivitamin or calcium supplement along with taking the study vitamin D3. Total vitamin D cannot exceed 5,800 IU per day combined between any supplements that contain vitamin D. Use of vitamin D at a daily dose > 5000 IU at the direction of a physician will be an exclusion criterion. If a potential subject uses over-the-counter vitamin D not directed by a physician at a daily dose > 5000 IU they will be eligible to participate by switching to the lower study dose.

Study Design


Intervention

Dietary Supplement:
Vitamin D supplementation
Daily vitamin D3 supplementation (5000 IU)

Locations

Country Name City State
United States Cooper University Hospital Camden New Jersey

Sponsors (2)

Lead Sponsor Collaborator
The Cooper Health System Won Sook Chung Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Influenza-like illness Incidence of influenza-like illness 9 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3